Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.

Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD.

J Med Econ. 2013 Jul;16(7):877-87. doi: 10.3111/13696998.2013.802694. Epub 2013 May 22.

PMID:
23647483
2.

Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.

Hamid R, Loveman C, Millen J, Globe D, Corbell C, Colayco D, Stanisic S, Gultyaev D.

Pharmacoeconomics. 2015 Apr;33(4):381-93. doi: 10.1007/s40273-014-0245-8.

3.

Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.

Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD.

Clin Ther. 2013 Apr;35(4):414-24. doi: 10.1016/j.clinthera.2013.02.020. Epub 2013 Mar 20.

PMID:
23522658
4.

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.

Acta Neurol Scand. 2014 Jan;129(1):61-70. doi: 10.1111/ane.12171. Epub 2013 Sep 20.

5.

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.

Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub 2011 Aug 29.

PMID:
21883197
6.

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group.

Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.

PMID:
20487038
7.

Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.

Eur J Neurol. 2013 May;20(5):773-80. doi: 10.1111/ene.12062. Epub 2012 Dec 24.

PMID:
23278954
8.

The cost effectiveness of Botox in Italian patients with chronic migraine.

Ruggeri M.

Neurol Sci. 2014 May;35 Suppl 1:45-7. doi: 10.1007/s10072-014-1741-5.

PMID:
24867835
9.

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.

Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.

Neurology. 2011 Oct 11;77(15):1465-72. doi: 10.1212/WNL.0b013e318232ab65. Epub 2011 Sep 28.

PMID:
21956721
10.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

11.

Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.

Khalil M, Zafar HW, Quarshie V, Ahmed F.

J Headache Pain. 2014 Sep 1;15:54. doi: 10.1186/1129-2377-15-54.

12.

OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Frampton JE.

Drugs. 2012 Apr 16;72(6):825-45. doi: 10.2165/11208880-000000000-00000. Review.

PMID:
22468643
13.

Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.

Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF.

Headache. 2014 Nov-Dec;54(10):1565-73. doi: 10.1111/head.12456. Epub 2014 Oct 9.

14.

Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.

Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.

J Pain. 2015 Feb;16(2):164-75. doi: 10.1016/j.jpain.2014.11.004. Epub 2014 Nov 15.

PMID:
25464159
15.

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group.

Cephalalgia. 2010 Jul;30(7):793-803. doi: 10.1177/0333102410364676. Epub 2010 Mar 17.

PMID:
20647170
16.

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.

J Neurol Sci. 2013 Aug 15;331(1-2):48-56. doi: 10.1016/j.jns.2013.05.003. Epub 2013 Jun 19.

PMID:
23790235
18.

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group.

Cephalalgia. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677. Epub 2010 Mar 17.

PMID:
20647171
19.

Development of onabotulinumtoxinA for chronic migraine.

Whitcup SM, Turkel CC, DeGryse RE, Brin MF.

Ann N Y Acad Sci. 2014 Nov;1329:67-80. doi: 10.1111/nyas.12488. Epub 2014 Aug 18. Review.

20.

A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Mathew NT, Jaffri SF.

Headache. 2009 Nov-Dec;49(10):1466-78. doi: 10.1111/j.1526-4610.2009.01566.x.

PMID:
19912346

Supplemental Content

Support Center